NCI Perspective on Nanomedicine and Nanobiology

Larry Nagahara, Ph.D.

Nanotechnology Projects Manager

National Cancer Institute

Grand Challenges for Nanomedicine and Nanobiology Workshop

August 27, 2007

•~ 560,000 Americans will die of cancer this year

•~1,300,000 Americans will hear the words “you have cancer…” this year

•~$185 billion per year on healthcare costs – for cancer in the U.S. alone

We Must Accelerate Progress Against Cancer: Early Diagnostics Is KeyWe Must Accelerate Progress Against Cancer: Early Diagnostics Is Key

Early Diagnostics Is Key

NCI Website:http://www.cancer.gov/NCI Website:http://www.cancer.gov/

NCI Strategic Objectives and ProgressNCI Strategic Objectives and Progress

To Preempt Cancer at Every OpportunityUnderstand the Causes and Mechanisms of CancerAccelerate Progress in Cancer PreventionImprove Early Detection and DiagnosisDevelop Effective and Efficient Treatments

To Ensure the Best Outcomes for AllUnderstand the Factors that Influence Cancer OutcomesImprove the Quality of Cancer CareImprove the Quality of Life for Cancer Patients, Survivors, and Their FamiliesOvercome Cancer Health Disparities

Nanotechnology is a “disruptive technology” which will drive a new generation of cancer

diagnostic and therapeutic products, resulting in dramatically improved cancer outcomes

The Potential of Nanotechnology in CancerThe Potential of Nanotechnology in Cancer

Early detection – highly sensitive and specific sensors

In-vivo imaging – new contrast agents, localization

Therapeutics – local, on-particle delivery

The Alliance was launched…

NCI Nanotechnology Alliance - AwardsNCI Nanotechnology Alliance - Awards

Centers of Cancer Nanotechnology Excellence (8)

Cancer Nanotechnology Platform Partnerships (12)

Nanotechnology Platform for Targeting Solid Tumors, The Sidney Kimmel Cancer Center, San Diego, Calif.

Detecting Cancer Early with Targeted Nano-probes for Vascular Signatures, University of California, San Francisco, Calif.

Nanotechnology Platform for Pediatric Brain Cancer Imaging and Therapy, University of Washington, Seattle, Wash.

Near-Infrared Fluorescence Nanoparticles for Targeted Optical ImagingUniversity of Texas M. D. Anderson Cancer Center, Houston, Texas

Hybrid Nanoparticles in Imaging and Therapy of Prostate Cancer, University of Missouri, Columbia, Mo.

DNA-linked Dendrimer Nanoparticle Systems for Cancer Diagnosis and Treatment, University of Michigan, Ann Arbor, Mich.

Metallofullerene Nanoplatform for Imaging and Treating Infiltrative Tumor, Virginia Commonwealth University, Richmond, Va.

Novel Cancer Nanotechnology Platforms for Photodynamic Therapy and Imaging, Roswell Park Cancer Institute, Buffalo, N.Y.

Multifunctional Nanoparticles in Diagnosis and Therapy of Pancreatic Cancer, State University of New York, Buffalo, N.Y.

Integrated System for Cancer Biomarker Detection, Massachusetts Institute of Technology, Cambridge, Mass.

Nanotherapeutic Strategy for Multidrug Resistant Tumors, Northeastern University, Boston, Mass.

Photodestruction of Ovarian Cancer: ErbB3 Targeted Aptamer-Nanoparticle Conjugate, Massachusetts General Hospital, Boston, Mass. Carolina Center

of Cancer Nanotechnology Excellence, University of North Carolina, Chapel Hill, N.C.

Nanosystems Biology Cancer Center, California Institute of Technology, Pasadena, Calif.

Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer, University of California, San Diego, Calif.

Emory-Georgia Tech Nanotech-nology Center for Personalized and Predictive Oncology, Atlanta, Ga.

Nanomaterials for Cancer Diagnostics and Therapeutics, Northwestern University, Evanston, Ill.

The Siteman Center of Cancer Nanotechnology Excellence at Washington University, St. Louis, Mo.

Center for Cancer Nanotechnology Excellence Focused on Therapy Response, Stanford University, Palo Alto, Calif.

MIT-Harvard Center of Cancer Nanotechnology Excellence, Cambridge, Mass.

$145 Million/5 Years$145 Million/5 Years(2005-2010)(2005-2010)

Nanotechnology is an Enabler of New Solutions for CancerNanotechnology is an Enabler of New Solutions for Cancer

Early detection Imaging Therapy

• Molecular imaging and early detection

• In vivo imaging

• Reporters of efficacy

• Multifunctional therapeutics

• Prevention and control

• Research enablers

Focus Areas:

• What are the nanomechanics involved in making a cancer cells move?

Differentiating the Good, the Bad, & the Ugly Differentiating the Good, the Bad, & the Ugly

protrusion

adhesion

traction

de-adhesion

Milan Mrksich - NWU NWU CCNE

• CHECK IT OUT!!!The Alliance Website: http://nano.cancer.govThe Alliance Website: http://nano.cancer.gov

Piotr Grodzinski, Ph.D. Program DirectorEmail: grodzinp@mail.nih.gov

Larry Nagahara, Ph.D.Nanotechnology Projects ManagerEmail:  nagaharl@mail.nih.gov

Jerry Lee, Ph.D.Nanotechnology Projects ManagerEmail: leejerry@mail.nih.gov

Office of the DirectorNational Cancer Institute31 Center DriveMSC 2580 Rm. 10A52Bethesda, MD 20892-2580Phone: (301) 496-1550Fax:     (301) 496-7807

NCI 2008 Budget Request BreakdownNCI 2008 Budget Request Breakdown

Some examples of current callsSome examples of current calls

The National Cancer Institute (NCI) is interested in:1. Early detection of the disease using imaging2. In vitro early diagnostics: multiplexed sensitive

and specific sensors3. Multi-functional therapeutics and localized

therapy delivery4. Tools and approaches to interrogate,

understand, and manipulate single cells, structures, and molecules

NIH/CDC Small Business Innovation Research (SBIR) Contract Solicitation Contract proposal receipt date: NOVEMBER 5, 2007241 Multifunctional Therapeutics Based on Nanotechnology252 Nanotechnology Imaging and Sensing Platforms for Improved Diagnosis of Cancer